IL314694A - שיטות וקומפוזיציות למניעה או עיכוב של סוכרת מסוג 1 - Google Patents
שיטות וקומפוזיציות למניעה או עיכוב של סוכרת מסוג 1Info
- Publication number
- IL314694A IL314694A IL314694A IL31469424A IL314694A IL 314694 A IL314694 A IL 314694A IL 314694 A IL314694 A IL 314694A IL 31469424 A IL31469424 A IL 31469424A IL 314694 A IL314694 A IL 314694A
- Authority
- IL
- Israel
- Prior art keywords
- diabetes
- compositions
- preventing
- methods
- delaying type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263345365P | 2022-05-24 | 2022-05-24 | |
| US202263367992P | 2022-07-08 | 2022-07-08 | |
| US202263382382P | 2022-11-04 | 2022-11-04 | |
| US18/321,964 US20230382993A1 (en) | 2022-05-24 | 2023-05-23 | Methods and compositions for preventing or delaying type 1 diabetes |
| PCT/US2023/067357 WO2023230476A1 (en) | 2022-05-24 | 2023-05-23 | Methods and compositions for preventing or delaying type 1 diabetes |
| TW112119143A TW202411250A (zh) | 2022-05-24 | 2023-05-23 | 用於預防或延緩第一型糖尿病的方法及組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314694A true IL314694A (he) | 2024-10-01 |
Family
ID=88920022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314694A IL314694A (he) | 2022-05-24 | 2023-05-23 | שיטות וקומפוזיציות למניעה או עיכוב של סוכרת מסוג 1 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2025517856A (he) |
| KR (1) | KR20250017195A (he) |
| AU (2) | AU2023275531C1 (he) |
| CA (1) | CA3256691A1 (he) |
| IL (1) | IL314694A (he) |
| MX (1) | MX2024008438A (he) |
| WO (1) | WO2023230476A1 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022283271A1 (en) | 2021-05-24 | 2023-12-07 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CN121568962A (zh) * | 2023-07-27 | 2026-02-24 | 普瑞文森生物有限公司 | 治疗1型糖尿病的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58765B1 (sr) * | 2011-05-21 | 2019-06-28 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
| IL288024B2 (he) * | 2019-05-14 | 2025-12-01 | Provention Bio Inc | שיטות ותכשירים למניעת סכרת מסוג 1 |
| AU2021287998B2 (en) * | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
-
2023
- 2023-05-23 IL IL314694A patent/IL314694A/he unknown
- 2023-05-23 WO PCT/US2023/067357 patent/WO2023230476A1/en not_active Ceased
- 2023-05-23 MX MX2024008438A patent/MX2024008438A/es unknown
- 2023-05-23 CA CA3256691A patent/CA3256691A1/en active Pending
- 2023-05-23 KR KR1020247027118A patent/KR20250017195A/ko active Pending
- 2023-05-23 AU AU2023275531A patent/AU2023275531C1/en active Active
- 2023-05-23 JP JP2024547458A patent/JP2025517856A/ja active Pending
-
2025
- 2025-10-17 AU AU2025252600A patent/AU2025252600A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250017195A (ko) | 2025-02-04 |
| AU2023275531C1 (en) | 2026-01-22 |
| CA3256691A1 (en) | 2023-11-30 |
| WO2023230476A1 (en) | 2023-11-30 |
| JP2025517856A (ja) | 2025-06-12 |
| AU2023275531A1 (en) | 2024-07-18 |
| MX2024008438A (es) | 2024-09-18 |
| AU2023275531B2 (en) | 2025-07-17 |
| AU2025252600A1 (en) | 2025-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL314694A (he) | שיטות וקומפוזיציות למניעה או עיכוב של סוכרת מסוג 1 | |
| IL307721A (he) | תרכובות ושיטות לעיכוב ביטוי של רכיב 3 | |
| IL316981A (he) | שיטות והרכבים למניעה או טיפול באלרגיות למזון | |
| IL315486A (he) | תרכובות כוללות meai ו- n-acylethanolamines ושימושים שלהם | |
| PL4069278T3 (pl) | Sposoby i kompozycje do zapobiegania cukrzycy typu 1 | |
| HK40122704A (en) | Methods and compositions for preventing or delaying type 1 diabetes | |
| HK40095886A (en) | Methods and compositions for preventing type 1 diabetes | |
| EP4164689A4 (en) | METHODS AND COMPOSITIONS FOR PREVENTING TYPE 1 DIABETES | |
| GB202215065D0 (en) | Compositions and uses thereof | |
| GB202209335D0 (en) | Compositions and uses thereof | |
| EP4054558A4 (en) | METHODS AND COMPOSITIONS FOR TREATING TYPE 2 DIABETES | |
| HK40089082A (en) | Methods and compositions for the treatment and prevention of type 1 diabetes | |
| HK40105632A (en) | Compositions and methods for inhibiting complement component 3 expression | |
| GB202216227D0 (en) | Composition and uses thereof | |
| GB2635318B (en) | Methods and compositions | |
| CA3263268A1 (en) | HEMORRHAGE-INHIBITING COMPOSITIONS AND PROCESSES INVOLVING THEM | |
| HK40087822A (en) | Compositions and methods for treating or preventing pulmonary hypertension | |
| GB202410495D0 (en) | Composition and uses thereof | |
| GB202402961D0 (en) | Composition and uses thereof | |
| CA3288518A1 (en) | Modified trems, compositions, and related methods thereof | |
| HK40101234A (en) | Methods and compositions for high-potency polypeptide-based protein inhibition | |
| EP4314018A4 (en) | Polypeptide-based protein inhibition methods and compositions with high sweetness | |
| HK40119848A (en) | Compositions and methods for inhibiting complement factor b | |
| GB202306393D0 (en) | Trna-based methods and related compositions | |
| GB202215064D0 (en) | Compositions and uses thereof |